Literature DB >> 9756849

The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate.

T Lind1, F Tufaro, C McCormick, U Lindahl, K Lidholt.   

Abstract

Hereditary multiple exostoses, characterized by multiple cartilaginous tumors, is ascribed to mutations at three distinct loci, denoted EXT1-3. Here, we report the purification of a protein from bovine serum that harbored the D-glucuronyl (GlcA) and N-acetyl-D-glucosaminyl (GlcNAc) transferase activities required for biosynthesis of the glycosaminoglycan, heparan sulfate (HS). This protein was identified as EXT2. Expression of EXT2 yielded a protein with both glycosyltransferase activities. Moreover, EXT1, previously found to rescue defective HS biosynthesis (McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L. E., Dyer, A. P., and Tufaro, F. (1998) Nat. Genet. 19, 158-161), was shown to elevate the low GlcA and GlcNAc transferase levels of mutant cells. Thus at least two members of the EXT family of tumor suppressors encode glycosyltransferases involved in the chain elongation step of HS biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756849     DOI: 10.1074/jbc.273.41.26265

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  107 in total

1.  The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis.

Authors:  C Senay; T Lind; K Muguruma; Y Tone; H Kitagawa; K Sugahara; K Lidholt; U Lindahl; M Kusche-Gullberg
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

2.  The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.

Authors:  C McCormick; G Duncan; K T Goutsos; F Tufaro
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Enzyme interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo.

Authors:  M A Pinhal; B Smith; S Olson; J Aikawa; K Kimata; J D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 4.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.

Authors:  Kazu Matsumoto; Fumitoshi Irie; Susan Mackem; Yu Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 6.  Organization of Golgi glycosyltransferases in membranes: complexity via complexes.

Authors:  W W Young
Journal:  J Membr Biol       Date:  2004-03-01       Impact factor: 1.843

7.  Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder.

Authors:  L J M Spaapen; J A Bakker; S B van der Meer; H J Sijstermans; R A Steet; R A Wevers; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 8.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

9.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

10.  The molecular and cellular basis of exostosis formation in hereditary multiple exostoses.

Authors:  Meirav Trebicz-Geffen; Dror Robinson; Zoharia Evron; Tova Glaser; Mati Fridkin; Yehuda Kollander; Israel Vlodavsky; Neta Ilan; Kit Fong Law; Kathryn S E Cheah; Danny Chan; Haim Werner; Zvi Nevo
Journal:  Int J Exp Pathol       Date:  2008-04-30       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.